Mallinckrodt and MBI file PMA for FS069
Mallinckrodt Medical and Molecular Biosystems have filed a premarketapproval (PMA) application for cardiac uses of MBI's second-generationFS069 ultrasound contrast agent. The companies said the PMA coversclinical studies in which FS069 was used for
Mallinckrodt Medical and Molecular Biosystems have filed a premarketapproval (PMA) application for cardiac uses of MBI's second-generationFS069 ultrasound contrast agent. The companies said the PMA coversclinical studies in which FS069 was used for enhancing endocardialborder delineation, as well as opacification of the left ventricularchamber. Doppler signal enhancement was also studied.
San Diego-based MBI is developing FS069 and has granted licensingrights for the agent to Mallinckrodt of St. Louis for North andSouth America, China, Australia, and New Zealand (SCAN 9/13/95).Both parties are hoping the agent will prove more successful thanAlbunex, MBI's first-generation agent, which has received a tepidresponse from the ultrasound community since it was introducedin 1994. Mallinckrodt also markets Albunex.
A phase III clinical trial conducted for FS069's PMA comparedthe agent with Albunex, and demonstrated the newer agent's superiorityin providing endocardial border delineation as well as left ventricularcontrast enhancement, both of which improve visualization of cardiac-wallmotion and function.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
